Dr. Kolibaba discusses results from the phase 3 GENUINE study presented at the ASCO Annual Meeting

Jun 22, 2017

VIDEO: Addition of ublituximab to ibrutinib effective for high-risk chronic lymphocytic leukemia

CHICAGO — The addition of ublituximab to ibrutinib appeared safe and effective for patients with high-risk chronic lymphocytic leukemia, according to results from the phase 3 GENUINE study presented at the ASCO Annual Meeting.

Kathryn S. Kolibaba, MD, who practices with the U.S. Oncology Network at Compass Oncology, and colleagues compared ublituximab (TG-1101, TG Therapeutics) plus ibrutinib (Imbruvica; Pharmacyclics, Janssen) with ibrutinib alone in 126 patients with high-risk relapsed or refractory CLL.

“The antibody was very well tolerated. In fact, in terms of safety, there was a minor increase in neutropenia, none of it grade 3 or 4. So, we were delighted with how well tolerated the drug was,” Kolibaba said. “We’re excited about the complete remissions that have been achieved by adding ublituximab to ibrutinib and look forward to additional results over the next few months.” – by Kristie L. Kahl

Disclosure: Kolibaba reports honoraria from TG Therapeutics; consultant and advisory fees from Gilead Sciences and Seattle Genetics; research funding from Acerta Pharma, Amgen, Celgene, Cell Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Pharmacyclics, Seattle Genetics and TG Therapeutics; and travel, accommodations or expenses from TG Therapeutics.